Literature DB >> 11796367

Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.

Haruaki Tomioka1, Katsumasa Sato, Chiaki Sano, Keisuke Sano, Toshiaki Shimizu.   

Abstract

Mycobacterium tuberculosis and M. avium complex strains given intramacrophage passage (I-type) were compared with those cultured in a liquid medium (E-type) for their drug susceptibilities when they were replicating in Mono-Mac-6 macrophages or A-549 cells. Their intracellular susceptibilities to rifalazil, clarithromycin, and levofloxacin were decreased more in I-type organisms than in E-type organisms, except that their rifalazil susceptibility inside A-549 cells was markedly increased in I-type organisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796367      PMCID: PMC127060          DOI: 10.1128/AAC.46.2.519-521.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Evasion of host cell defense mechanisms by pathogenic bacteria.

Authors:  J Pieters
Journal:  Curr Opin Immunol       Date:  2001-02       Impact factor: 7.486

2.  A coat protein on phagosomes involved in the intracellular survival of mycobacteria.

Authors:  G Ferrari; H Langen; M Naito; J Pieters
Journal:  Cell       Date:  1999-05-14       Impact factor: 41.582

3.  Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells.

Authors:  K Sato; H Tomioka
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

Review 4.  Interactions between Mycobacterium tuberculosis and host cells: are mycobacterial sugars the key?

Authors:  M R Ehlers; M Daffé
Journal:  Trends Microbiol       Date:  1998-08       Impact factor: 17.079

5.  Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.

Authors:  R Dietze; L Teixeira; L M Rocha; M Palaci; J L Johnson; C Wells; L Rose; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.

Authors:  K Sato; H Tomioka; T Akaki; S Kawahara
Journal:  Int J Antimicrob Agents       Date:  2000-09       Impact factor: 5.283

Review 7.  Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.

Authors:  H Tomioka
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

8.  Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway.

Authors:  L E Bermudez; A Parker; J R Goodman
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

9.  Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis.

Authors:  K A McDonough; Y Kress
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Mycobacterium tuberculosis invades and replicates within type II alveolar cells.

Authors:  L E Bermudez; J Goodman
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

View more
  5 in total

1.  Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis- and cavitary-type diseases.

Authors:  Y Tatano; K Yasumoto; T Shimizu; C Sano; K Sato; S Yano; H Takeyama; H Tomioka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-04       Impact factor: 3.267

2.  A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.

Authors:  Firat Kaya; Jacqueline P Ernest; Katherine LoMauro; Martin Gengenbacher; Abdeldjalil Madani; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Jansy P Sarathy; Nadine Alvarez; Isaac Daudelin; Han Wang; Faye Lanni; Danielle M Weiner; Laura E Via; Clifton E Barry; Kenneth N Olivier; Thomas Dick; Brendan K Podell; Radojka M Savic; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2022-01-31       Impact factor: 5.938

3.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

4.  Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.

Authors:  Hanako Fukano; Kazue Nakanaga; Masamichi Goto; Mitsunori Yoshida; Norihisa Ishii; Yoshihiko Hoshino
Journal:  PLoS One       Date:  2022-10-06       Impact factor: 3.752

5.  Effect of mycobacterial secretory proteins on the cellular integrity and cytokine profile of type II alveolar epithelial cells.

Authors:  Nidhi Adlakha; Pooja Vir; Indu Verma
Journal:  Lung India       Date:  2012-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.